Product Description
Timolol is a medication used to treat and manage open-angle glaucoma and ocular hypertension. It is in the beta-blocker class of drugs. Timolol can also be used in some instances to treat infantile hemangiomas, hypertension, myocardial infarction, migraine prophylaxis, and atrial fibrillation. (Sourced from: https://www.ncbi.nlm.nih.gov/books/NBK545176/)
Mechanisms of Action: ADR Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Topical,Ophthalmic
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: Hypertension | Glaucoma | Hypertension | Glaucoma | Glaucoma, Open-Angle
Known Adverse Events: Hyperemia | Thyrotoxicosis | Pruritus | Muscle Weakness | General Diabetes | Conjunctivitis | Conjunctivitis, Allergic | Keratitis
Company: Alcon
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Belgium, Bulgaria, China, Germany, Greece, United States
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Capillary Hemangioma|Glaucoma|Glaucoma, Open-Angle|Hemangioma|Hypertension|Port-Wine Stain
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| EyeD-010-003 | P1 |
Recruiting |
Glaucoma, Open-Angle |
2027-07-01 |
|
| BECRO/OV/BRINZOTIM | P3 |
Unknown Status |
Glaucoma|Hypertension |
2025-06-30 |
|
| Non-inferiority study between two Latanoprost/Timolol formulations eye drops solution | P3 |
Active, not recruiting |
Hypertension|Glaucoma |
2024-08-08 |
|
| LT4030-301 | P3 |
Completed |
Hypertension|Glaucoma |
2023-04-13 |
95% |